U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148505) titled 'A Study of Real-world Outcomes Among Patients Treated With Ribociclib' on Aug. 21.
Brief Summary: The main aim of the study was to evaluate the real-world tolerability and safety of ribociclib as a first-line (1L) treatment among adults with hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC).
This study used data from the Flatiron Health Research Database (FHRD). The FHRD is a longitudinal database derived from electronic health records (EHRs) and other real-world data (RWD) sources from cancer care providers across the United States. The dataset generated for this...